History of GLP-1s: From Lizard Venom to Lifesaving Science

GLP-1s seemingly came out of nowhere.

One day, you hear a distant aunt lost all that weight on Ozempic. Next, it’s in every TikTok and celebrity interview. Suddenly, there’s a weight-loss drug that actually works, and it works like nothing ever has.

Of course, a breakthrough like this comes with sensational headlines, like “Ozempic Literally Came From a Monster – And It’s Not Alone,” conjuring concerns about short-term safety and long-term side effects.^[1]

To really understand where these medications came from and how safe they are, we have to go further back in history than you might realize.

The Obesity Epidemic in America

What Is Obesity?

Most people still believe the old-school idea that weight is just about what you eat and how much you move, and while those factors do matter, they’re a fraction of the story.

Obesity is now recognized as a chronic, relapsing, multifactorial disease, meaning it’s caused by many overlapping factors working against you at the same time.^[2]

And while it’s true that multiple issues play a role, it’s clear that one culprit still takes the cake.

Obesity Rates in America

By the time GLP-1s were making headlines, obesity had already become one of the leading drivers of death and disability in America.

^[3][4][5]

Between 1976 and 1980, obesity rates started climbing across every age, gender, and background, and with them, the risk of serious health issues like heart disease, stroke, type 2 diabetes, and some cancers.^[6] 

Why? Because the world around us changed faster than our biology could keep up, but there’s one thing that changed almost overnight: the American diet.

The late 1970s kicked off a total food revolution. Fast food exploded into the market, cheap, quick, and everywhere you looked. But this wasn’t your average home-cooked meal. These were ultra-processed foods and sugary drinks, carefully engineered to make us come back for more.

These foods hijack the brain’s reward system, overriding fullness signals and lighting up dopamine like a slot machine.^[7] You eat, you get a hit, you crave the next one.

That’s why food is considered the match that lit the fire. The timing and data align with the biological shift.

What Causes Obesity?

While food may have sparked the initial change, today the picture is far more complex, fueled by an entire ecosystem of modern pressures outlined below.

Here are just a few of the key drivers:

Factor	How it contributes
Fitness	Low physical activity levels due to sedentary work environments, prolonged screen exposure, and limited daily movement can cause extra calories to be stored as fat.
Food	Ultra-processed foods dominate the modern diet. They’re cheap, convenient, and engineered to trigger reward pathways, making overeating easy and fullness hard to reach.
Environment	Some neighborhoods have grocery stores and green spaces; others face food deserts and targeted marketing. These gaps may limit nutritional choices and drive health disparities.
Chemicals	Everyday chemicals like BPA, phthalates, and pesticides act as obesogens, disrupting hormones and promoting fat storage even at low levels.
Genetics	Genes account for 40%–70% of obesity risk. Family history shapes appetite, energy use, and fat storage, and today’s calorie-dense environment amplifies those tendencies.
Health	Conditions like PCOS, hypothyroidism, insulin resistance, certain medications, and even mental health can all influence obesity.[8]

Over the last 40 years nearly every single one of these risk factors has worsened.

On top of this, obesity is chronic, which means it keeps coming back. In a meta-analysis of 29 long-term weight loss studies, people regained more than half of the weight they lost within two years, and by five years they had regained over 80% of it.^[9] The body fights back, trapping people in a cycle of losing and regaining.

That cycle persisted, and the national average kept rising, until something unexpected happened.

GLP-1s were approved for weight loss, and the numbers stopped rising.

Was this just a coincidence?

The Science of GLP-1s

What Are GLP-1s?

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after you eat.^[10] It belongs to a family of gut hormones called incretins, which help your body manage blood sugar and digestion.

It helps your body in a few key ways:

• It slows down how quickly food leaves your stomach, so you feel fuller longer.
  
• It tells your pancreas to release insulin when blood sugar rises.
  
• It sends signals to your brain that help regulate appetite and energy use.^[10]

Think of hormones as your body texting your brain little messages that say things like “I’m hungry,” “I’m full,” or “Let’s burn some energy.” GLP-1 is one of the main messengers in that chat.

When a person has obesity, the gut sends messages, but some never deliver and others show up missing half the message. With that signal broken, the brain never gets the full picture, so hunger hangs around longer than it should.

In this case, GLP-1 medications act like a Wi-Fi boost your body didn’t know it needed. No more missing notifications. Your gut-to-brain messages finally send, deliver, and read like they’re supposed to.

The active ingredients in GLP-1 drugs are receptor agonists, compounds that attach to a receptor, the signal receiver on your cells, and activate it. This triggers the same response your body’s natural hormone would.

They mimic its effect by binding to the GLP-1 receptor and activating the same pathways your body would normally use.

By doing this, they boost the signal, not just for GLP-1 itself, but for the whole network of hormones that help regulate hunger and fullness. They work alongside ghrelin (which increases appetite) and leptin (which decreases it), getting your hunger hormones back on speaking terms—no more ghosting or mixed messages, and finally, no more food noise.^[11] 

And while food noise might be the buzzword of the year, the science that silences it has been building for decades.

GLP-1s and Lizard Venom 

In the early 1980s, scientists studying the gene that produces glucagon, a hormone that raises blood sugar, discovered it also contained instructions for another hormone, later named GLP-1.

Fast-forward to the 1990s, when a biochemist studying the Gila monster, a venomous desert lizard, found something fascinating in its saliva: a compound called exendin-4.^[10] It looked almost identical to human GLP-1 but lasted much longer in the body, staying active instead of breaking down within minutes.

It’s true that GLP-1 drugs were inspired by lizard venom. No actual venom involved though, just one brilliant idea that changed modern medicine and led to the creation of the first GLP-1 medication for type 2 diabetes.

Types of GLP-1s

Daily Injections

Exenatide (Byetta)

Byetta® became the first GLP-1-based medication, approved by the FDA in 2005 as an add-on therapy to metformin and/or sulfonylureas for type 2 diabetes.

It was injected subcutaneously into the fatty layer just under the skin and offered an advantage over insulin and sulfonylureas because it lowered blood sugar without causing hypoglycemia.^[12]

The downside was its short half-life, which meant injecting twice a day and made long-term use difficult. So researchers got to work finding a way to make that magic last longer.

Liraglutide (Victoza/Saxenda)

Approved in 2010 as Victoza® for type 2 diabetes, it became one of the first once-daily GLP-1 shots. In the LEAD clinical trials, it lowered average A1C by around 1.5% and helped nearly half of patients reach target levels.^[13] It also improved fasting glucose and led to a few pounds of weight loss on average.

A higher dose later became Saxenda®, approved for chronic weight management. People lost about 5% of their body weight on average, proving real, sustained weight loss was possible. Then the 2016 LEADER trial showed Victoza also cut major heart risks, making liraglutide the first GLP-1 proven to save lives, not just lower blood sugar.^[12] 

Still, daily injections weren’t ideal, and researchers began exploring ways to make GLP-1s last longer.

They used something called pharmacokinetic modeling to map how a drug moves through and stays in the body and predict that weekly versions could work even before some Phase 2 trials were finished.

These new formulations stayed active longer, offering more stable control and easier dosing. This was a turning point that led to the next leap: weekly dosing.

Weekly GLP-1 Monotherapy

Dulaglutide (Trulicity)

Approved in 2014, Trulicity® became the first GLP-1 available in a ready-to-use autoinjector “pen.” It provided steady blood sugar control and modest weight loss with just one injection per week.

In the REWIND trial, dulaglutide cut major heart events by 12%, proving GLP-1s protect the heart, not just blood sugar.^[15] 

This officially put GLP-1s in a whole new league.

Semaglutide (Ozempic/Rybelsus/Wegovy)

After the early drugs set the stage, semaglutide stepped onto the red carpet and stole the show.

Approved in 2017 as Ozempic® for type 2 diabetes, it offered once-weekly dosing with powerful results: significantly lowering blood sugar, reducing A1C by over 1%, and cutting the risk of major cardiovascular events like heart attack and stroke in high-risk patients.^[16]

This was followed by the first ever oral GLP-1, Rybelsus®, which was approved just two years later in 2019, offering semaglutide in a pill form for type 2 diabetes.

Rybelsus works well for blood sugar and provides a convenient option for people who prefer pills, but it comes with a specific dosing routine:

• Must be taken on an empty stomach with only a tiny sip of water (up to 4 oz)
• Must wait at least 30 minutes before eating or drinking

Because of that, many people still preferred the weekly injection for its ease and consistency.

But here’s where things got interesting. During the clinical trials, people taking Ozempic started losing weight, and not just a little.

Patients on the standard 1.0 mg dose lost an average of 2.3 to 6.3 kilograms (5 to 14 pounds) in the SUSTAIN trials for type 2 diabetes.^[16] What began as a side effect quickly became the main event.

Earlier GLP-1s like liraglutide (Saxenda) had already shown that this class could help with modest weight loss, which was impressive at the time.^[17] But semaglutide blew those numbers out of the water.

Wegovy® is a higher-dose version of semaglutide that was approved in 2021 specifically for weight loss. In the STEP 1 clinical trial, Wegovy delivered blockbuster results: an average of around 15% total body weight loss over 68 weeks at the 2.4 mg dose.^[18]

That kind of weight loss was similar to the lower end of surgical results, like gastric banding or sleeve gastrectomy, which usually lead to about 15%–25% loss.

Seeing that from a weekly shot was unheard of. But the real shock wasn’t just the numbers. It was the validation. Wegovy showed that obesity isn’t about willpower. It’s a biological disease with a medical solution, and it opened the door to even more innovation.

Scientists began exploring ways to build on that success, combining GLP-1s with other hormones to make them even more powerful.

Dual and Triple Agonists

Tirzepatide (Mounjaro/Zepbound)

Tirzepatide is the first true dual or co-agonist, activating both GLP-1 and GIP receptors, a pairing often called a twincretin. It made its debut in 2022 as Mounjaro® for type 2 diabetes and later as Zepbound® for obesity in 2023.

GIP, short for glucose-dependent insulinotropic polypeptide, is like your body’s little food alert. It tells your system, “Hey, food’s here!” and helps release insulin only when your blood sugar rises, like after a meal.

By targeting two incretin pathways instead of one, tirzepatide takes metabolic control to a whole new level.

In people with type 2 diabetes, the SURPASS trials showed tirzepatide produced greater weight loss and better blood sugar control than other GLP-1s, including semaglutide. It also protected the heart just as well as Trulicity, with early signs suggesting even stronger cardiovascular benefits.

In the SURPASS-CVOT trial, tirzepatide protected the heart just as well as dulaglutide, and early signs suggest it may work even better in people with type 2 diabetes at high cardiovascular risk.^[19]

But the SURMOUNT trial sealed the deal, showing tirzepatide led to around a 20% average body weight loss compared to about 14% on semaglutide, setting a whole new standard for what’s possible.^[20] 

Tirzepatide didn’t just raise the bar, it reset the new standard, and triple agonists are already pulling up to take on the challenge.

Retatrutide

An obesity specialist once described GLP-1s to me like iPhones: always evolving, with each new generation becoming smarter, more refined, and more effective than the last.

If tirzepatide redefined what was possible, retatrutide is the next frontier.

Retatrutide is a triple agonist that activates three incretin-related pathways: GLP-1, GIP, and glucagon.

Glucagon works by telling the liver to release stored sugar so the body has energy to use. Together with its effects on GLP-1 and GIP, retatrutide may help boost metabolism and even improve cholesterol levels by lowering LDL.

Retatrutide didn’t just keep up with tirzepatide, it pulled ahead.

In studies, it delivered up to around 24% average total body weight loss in just 48 weeks on the 12 mg dose.^[21] For the first time in medical history, drug-based treatments are rivaling the effects of bariatric surgery.

Retatrutide is on track to set a new record for nonsurgical weight loss.

The Next GLP-1s

The innovation doesn’t stop there.

CagriSema is a next-generation dual agonist that combines semaglutide and cagrilintide. In the REDEFINE-1 trial, it led to an average of around 20% weight loss over 68 weeks, rivaling tirzepatide and exceeding semaglutide alone.^[22] 

Cagrilintide is a synthetic (lab-made) version of amylin, a natural hormone released by the pancreas after you eat. It helps slow digestion, increases feelings of fullness, and regulates blood sugar, but it’s designed to last longer and work better than natural amylin.

Even semaglutide is working on pushing boundaries, in higher doses. In a Phase 3 study called the Step-Up trial, people taking the 7.2 mg dose lost almost 19% of their body weight on average. That’s about the same as what people lost with tirzepatide.^[23] 

It showed that even without changing the medicine itself, a higher dose can make a big difference.

But new molecules are also on the way.

A new oral medication for weight loss called orforglipron is showing promising results. It’s a small-molecule GLP-1 that isn’t a peptide, which means no refrigeration, no injections, and potentially lower manufacturing costs.

In the ATTAIN-1 trial, people taking the highest dose lost around 8% to 11% of their body weight. That’s less than Wegovy, but orforglipron’s big advantage is convenience.^[24] 

It works in pill form instead of an injection while still improving blood pressure, cholesterol, and blood sugar, as well as helping most people with prediabetes return to normal levels. It’s an early sign that the future of GLP-1 therapy could be as simple as taking a daily tablet without the schedule and food restrictions of current oral treatments (Rybelsus).

It’s an exciting time for science and obesity medicine. Beyond the scale, people are seeing major improvements in their overall health.

GLP-1 Health Benefits

Weight-Related Health Benefits

GLP-1s are changing everything. Researchers are discovering benefits that go far beyond weight loss. Below are a few examples backed by solid scientific evidence.

Target area	Benefit
Heart	In the SELECT trial of more than 17,000 adults with obesity and heart disease, weekly semaglutide lowered the risk of heart attack, stroke, or heart-related death by 20%.[25] And in people with heart failure with preserved ejection fraction (HFpEF), a 2025 meta-analysis found that semaglutide or tirzepatide cut the combined risk of death or hospitalization by 27%.[26]This showed that long-term GLP-1 use helps the heart work more efficiently, lowers blood pressure and LDL, and provides lasting protection against heart disease and related death.
Kidneys	Semaglutide helps protect the kidneys and slow down damage over time. In the FLOW study, people taking semaglutide were 24% less likely to have kidney failure or major kidney decline compared with those on placebo.[27] Overall, it helped preserve kidney function and delay disease progression throughout the study.
Liver (MASH/NAFLD)	Reduces inflammation and fibrosis in fatty liver disease, showing that meaningful weight loss can actually help the liver repair and regenerate. In a Phase 3 trial, around 63% of patients on semaglutide achieved resolution of MASH, while only 34% of those on a placebo achieved the same result.[28]
Cancer	Studies show that GLP-1 users have a 17% lower overall cancer risk. Across specific cancers, studies report significant reductions: roughly 25% lower endometrial cancer risk, 47% lower ovarian cancer risk, and 31% lower meningioma risk.[29] Animal data supports direct anti-tumor effects too.
Obstructive sleep apnea	The SURMOUNT-OSA trial showed that tirzepatide significantly reduced the number of breathing interruptions during sleep in people with obstructive sleep apnea.[30] Based on these results, the FDA approved Zepbound for the treatment of moderate to severe obstructive sleep apnea in adults with obesity in 2024. GLP-1s may help treat this condition by reducing fat buildup around the upper airway and decreasing systemic inflammation.[31]
Eyes	Observational data suggest that GLP-1s are linked to a lower risk of glaucoma. However, the potential benefits still need to be confirmed.[32] They’re also associated with a potentially lower risk of dry eye or keratitis and age-related macular degeneration. However, there have been rare reports of early diabetic-retinopathy worsening in patients with rapid A1c drops.

We’re still just scratching the surface. Every new study seems to reveal a new layer of potential health benefits.

Health Benefits Beyond the Scale

GLP-1s are showing signs that their impact might extend far beyond weight loss and metabolic control.

Early studies suggest GLP-1s can support healthy brain function by improving how the brain uses energy and how different regions communicate.

In a year-long trial of just over 200 people with mild to moderate Alzheimer’s, liraglutide helped preserve brain volume in key areas and strengthened connections in key memory networks seen on brain scans.^[33]

Another study highlighted in a large review found that people using GLP-1 medicines had a 23%–31% lower chance of developing dementia than those on other diabetes drugs, specifically sulfonylureas and DPP-4 inhibitors.^[34] New, large-scale trials with semaglutide and tirzepatide are now underway to learn whether these drugs can actively protect the brain.

With that kind of neural activity, it’s no wonder GLP-1s are also showing promise for mental health and addiction.

Across six clinical studies, people taking GLP-1 medications, especially liraglutide, produced a small but statistically significant improvement in depression ratings versus controls.^[35] The mood boost was modest but real, hinting that these drugs may touch brain circuits far beyond metabolism.

Animal studies back it up, showing GLP-1s reduce the dopamine-driven reward response behind alcohol, nicotine, cocaine, and opioid use. In humans, data is limited, but some studies suggest reduced cravings and other benefits in people trying to quit smoking.^[36]

It’s early, but it’s clear GLP-1s aren’t just changing the scale, they’re redefining what’s possible for longevity itself. So it’s no surprise that somewhere between TikTok trends and celebrity confessions, the world collectively lost its mind over them.

Chronic Disease Management

GLP-1 Side Effects

Now that we know why GLP-1s are hailed as miracle drugs, it can’t be all good, right?

After decades of rising obesity rates, GLP-1s have done what no other treatment could, and it all comes down to something that sounds surprisingly simple.

GLP-1s work by slowing gastric emptying and regulating appetite signals in the brain, helping you feel full sooner and stay satisfied longer. This quiets the constant “food noise” that drives overeating.

The same process can also cause side effects like nausea and constipation. Nausea usually fades as your body adjusts, while constipation improves with hydration, fiber, and movement.

You can find a full breakdown of other common side effects like diarrhea, bloating, and indigestion, as well as learning how to manage them, by reading our comprehensive guide on GLP-1 side effects.

Chronic Use Imperative

If obesity is a chronic, relapsing disease, then it makes sense that GLP-1s only work while you take them.

In the STEP-1 trial, participants who stopped semaglutide regained 11.6% of lost weight within a year, keeping only about 5.6% off long-term.^[37] 

The SURMOUNT-4 trial found the same with tirzepatide: Once treatment stopped, people regained around 14% of their body weight.^[37]

A 2025 meta-analysis confirmed this pattern across all major GLP-1s, showing average regain of 2–10 kgs (4–22 lbs) depending on the medication and duration.^[37]

It’s the same pattern we see with other lifelong conditions, such as high blood pressure or cholesterol. When treatment ends, the body returns to its old settings, hunger hormones rise, metabolism slows, and fat stores rebound.

The science couldn’t be clearer: GLP-1s aren’t short-term fixes. Obesity requires long-term care and lifestyle interventions.

Lifestyle Interventions

GLP-1s aren’t a free pass to skip the gym or coast on caffeine.

A 2024 eClinicalMedicine study from the University of Copenhagen found that combining liraglutide with exercise led to around 5 kg (11 lbs) more weight loss maintained and a 2.3% lower body-fat one year after stopping treatment, significantly better long-term results than medication alone.^[38]

The body naturally loses lean mass when it isn’t challenged, which is why strength training matters. It protects muscle while promoting fat loss.

The good news is the idea that GLP-1s “melt muscle” doesn’t hold up. Tirzepatide’s lean-mass changes are similar to what’s seen in any major weight-loss program, but that doesn’t make it any less important to train.

Exercise and nutrition are essential for health and safe treatment with a GLP-1, especially when paired with the right dosing strategy to minimize side effects and support sustainable progress.

Dosing Strategy

Finding the right GLP-1 dose isn’t about climbing the ladder to the top, it’s about landing on the lowest effective dose that quiets food noise, keeps you steady, and minimizes side effects.

A 2025 Diabetes, Obesity and Metabolism study found that reducing dosing frequency (from once weekly to every two weeks) maintained about 70%–75% of total weight loss while cutting costs by up to 50%.^[39] 

In some models, adjusting the dose amount kept nearly 100% of the weight loss even at half the frequency.^[39] Once your weight stabilizes, the goal is to stay on the lowest effective dose, the one that maintains those results while minimizing side effects.

Because success isn’t just about reaching a number on the scale; it’s about how your whole body feels, functions, and continues to benefit over time.

History of GLP-1 FDA Approvals 

Approved Indications

Seemingly overnight, medications that once hid in the quiet corner of diabetes care became the hottest thing in weight loss. This forced drug companies to go back to the FDA for a second approval, as every new use indication needs its own official stamp.

That’s why you see two names for the same drug. They’re chemically identical. The only thing that changed was the dosage, label, and clinical trials that got them approved for chronic weight management.

Swipe to scroll the table below →

Drug (active ingredient)	Brand name	Approved indication	Original FDA approval date	Date added to FDA shortage list	Date shortage declared resolved by FDA
Liraglutide	Victoza	Type 2 diabetes	January 25, 2010	July 20, 2023	Ongoing*
Dulaglutide	Trulicity	Type 2 diabetes	September 12, 2014	August 19, 2022	Ongoing*
Liraglutide	Saxenda	Obesity	December 23, 2014	April 2024	February 21, 2025
Semaglutide	Ozempic	Type 2 diabetes	December 5, 2017	August 23, 2022	February 21, 2025
Semaglutide	Rybelsus	Type 2 diabetes	September 20, 2019	N/A	N/A
Semaglutide	Wegovy	Obesity	June 4, 2021	March 31, 2022	February 21, 2025
Tirzepatide	Mounjaro	Type 2 diabetes	May 13, 2022	December 2022	December 19, 2024
Tirzepatide	Zepbound	Obesity/OSA	November 8, 2023	April 3, 2024	December 19, 2024
Note: This table includes only the GLP-1 medications discussed in this article. It does not represent a complete list of all existing or lesser-known GLP-1s.

Wegovy launched, and within a year it was on the shortage list. The results were undeniable. People were losing life-changing amounts of weight, and demand exploded.

As pharmacies ran dry, prescribers pivoted to Ozempic, prescribing it off-label for weight loss, but pharmacies couldn’t keep up, even in the United States, where production is highest. Nationwide backorders made it nearly impossible to find.

Mounjaro launched and within months, it followed suit.

Nearly a year later, Zepbound hit the market, and for a moment, it looked like relief had finally arrived. But it was déjà vu all over again—less than six months after release, it too landed on the shortage list.

Drug Shortage List

When a drug goes into shortage, compounding pharmacies step in to help fill the gap. It’s not a loophole; it’s the FDA’s built-in safety system designed to keep patients from losing access.

There are two different types of compounding pharmacies:

• 503A pharmacies: Small, state-licensed pharmacies that work one-on-one with patients. They can make exact copies during shortages, but their main function is to create individualized prescriptions, like adjusting the dose or removing an allergen when the brand name doesn’t work.^[40]
• 503B pharmacies: FDA-regulated facilities that can mass produce exact copies of the brand-name drug during official shortages.^[40] 

When the FDA resolved the shortages, 503B pharmacies had to shut down GLP-1 production, but 503A pharmacies continued doing what they exist for: making personalized, prescription-by-prescription versions.

GLP-1 Legal Landscape

The drug makers weren’t thrilled. As cheaper compounded versions kept popping up online, Novo Nordisk and Eli Lilly launched an aggressive crackdown, sending out hundreds of cease-and-desist letters and filing dozens of lawsuits across the country.

Their message was clear: This market belongs to them.

What started as a temporary lifeline for patients during shortages has turned into a turf war over a multibillion-dollar industry, with one major issue, affordable access.

Barriers to Access and the Road Ahead

Cost and Access Barriers

The biggest barrier to GLP-1 access is cost.

In the US, there’s no regulation on drug pricing. Pharmacy benefit managers (PBMs) negotiate rebates from manufacturers to secure insurance coverage, but those rebates may sometimes reach more than 50% of a drug’s list price. They then decide how much of those rebates are passed to payers or patients.

Manufacturers set list prices high knowing that most of that price will be discounted via rebate. For example, let’s say the manufacturer sets the list price to $1,200, knowing they’ll have to pay back roughly half of it to PBMs. In this example the PBM pockets about $600, the manufacturer nets $600, and the insurer can still end up paying inflated costs for every prescription.

By early 2025, many insurers and employers dropped GLP-1 coverage entirely, leaving patients with often over $1,000 in out-of-pocket costs.

At the same time, ongoing nationwide shortages made access nearly impossible even for those with coverage. Some patients were forced to call “100 pharmacies in their state, just trying to find their dose.^[41]

Many patients turned to compounded versions as their only option.

Compounded GLP-1s

When the brand-name medications went into shortage, 503A and 503B compounding pharmacies filled the gap, offering versions at a fraction of the price. For many patients it was a lifeline.

These weren’t “black market” copies or counterfeits. This is exactly how they are legally meant to operate.

Pharmaceutical companies quickly pushed back. They funded safety campaigns warning that compounded GLP-1s weren’t FDA-approved, raising doubts about their safety, quality, and effectiveness.

The messaging leaned heavily on words like “loophole” and “risk,” framing compounding as rule-bending rather than a built-in safeguard.

Major organizations, including the American Diabetes Association (ADA), echoed this position and publicly advised against using non-FDA-approved compounded incretin products.

Critics argue that the overlap between those talking points and pharmaceutical messaging, especially from nonprofits that receive industry funding, didn’t just create confusion; it scared people.

In the end, patients are still stuck in the middle of a messaging and legal battlefield.

GLP-1 Access in the Future

People often ask me what the future of affordable GLP-1 access looks like. The truth is, it’s uncertain but moving in the right direction.

What’s clear is that competition will reshape the landscape. Compounded options pushed manufacturers to launch $500 cash-pay programs. Medications cost half the original price but were still not affordable for most. As more manufacturers enter the market and new formulations emerge, prices should continue to fall.

We’re not there yet, but we’re seeing progress. What started as a luxury treatment is slowly becoming a cornerstone of modern metabolic care.

FAQs

Sources

1. Cockerill, J. (2025, February 21). Ozempic literally came from a monster – and it’s not alone. ScienceAlert. https://www.sciencealert.com/ozempic-literally-came-from-a-monster-and-its-not-alone
2. De Lorenzo, A., Romano, L., Di Renzo, L., Di Lorenzo, N., Cenname, G., & Gualtieri, P. (2020). Obesity: A preventable, treatable, but relapsing disease. Nutrition, 71, 110615. https://doi.org/10.1016/j.nut.2019.110615
3. Centers for Diseases Control and Prevention. (2024, May 14). Adult obesity facts. https://www.cdc.gov/obesity/adult-obesity-facts/index.html
4. Emmerich, S. D., Fryar, C. D., Stierman, B., Gu, Q., Afful, J., & Ogden, C. L. (2025). Trends in obesity-related measures among US children, adolescents, and adults. JAMA, 333(12), 1082–1084. https://doi.org/10.1001/jama.2024.27676
5. Centers for Diseases Control and Prevention. (2024, April 2). Childhood obesity facts. https://www.cdc.gov/obesity/childhood-obesity-facts/childhood-obesity-facts.html
6. Ahmed, S. K., & Mohammed, R. A. (2025). Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions. Metabolism Open, 100375. https://doi.org/10.1016/j.metop.2025.100375
7. Kalon, E., Hong, J. Y., Tobin, C., & Schulte, T. (2016). Psychological and neurobiological correlates of food addiction. International Review of Neurobiology, 129, 85–110. https://doi.org/10.1016/bs.irn.2016.06.003
8. Masood, B., & Moorthy, M. (2023). Causes of obesity: a review. Clinical Medicine, 23(4), 284–291. https://doi.org/10.7861/clinmed.2023-0168
9. Hall, K. D., & Kahan, S. (2018). Maintenance of lost weight and long-term management of obesity. Medical Clinics, 102(1), 183–197. https://doi.org/10.1016/j.mcna.2017.08.012
10. Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T .W., Seeley, R. J., Stemmer, K., Tang-Christensen, M., Woods, S. C., DiMarchi, R. D., & Tschöp, M. H. (2019). Glucagon-like peptide (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
11. Ronveaux, C. C., Tomé, D., & Raybould, H. E. (2015). Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. The Journal of Nutrition, 145(4), 672–680. https://doi.org/10.3945/jn.114.206029
12. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., & Steinberg, W. M. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827
13. Jackson, S. H., Martin, T. S., Jones, J. D., Seal, D., & Emanuel, F. (2010). Liraglutide (Victoza): The first once-daily incretin mimetic injection for type-2 diabetes. Pharmacy and Therapeutics, 35(9), 498. https://pmc.ncbi.nlm.nih.gov/articles/PMC2957743/
14. Iwasaki, S., Hamada, T., Chisaki, I., Andou, T., Sano, N., Furuta, A., & Amano, N. (2017). Mechanism-based pharmacokinetic/pharmacodynamic modeling of the glucagon-like peptide-1 receptor agonist exenatide to characterize its antiobesity effects in diet-induced obese mice. The Journal of Pharmacology and Experimental Therapeutics, 362(3), 441–449. https://doi.org/10.1124/jpet.117.242651
15. Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., & Xavier, D. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. The Lancet, 394(10193), 121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
16. Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P., Birch, S., Holst, A. G., & Leiter, L. A. (2018). Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, Obesity and Metabolism, 20(9), 2210–2219. https://doi.org/10.1111/dom.13353
17. Mehta, A., Marso, S. P., & Neeland, I. (2017). Liraglutide for weight management: A critical review of the evidence. Obesity Science & Practice, 3(1), 3–14. https://doi.org/10.1002/osp4.84
18. Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022). Wegovy (semaglutide): A new weight loss drug for chronic weight management. Journal of Investigative Medicine, 70(1), 5–13. https://doi.org/10.1136/jim-2021-001952
19. Nicholls, S. J., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., & Zinman, B. (2024). Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics. American Heart Journal, 267, 1–11. https://doi.org/10.1016/j.ahj.2023.09.007
20. Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 393(1), 26–36. https://doi.org/10.1056/NEJMoa2416394
21. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M.L. (2023). Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
22. Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., & Wilding, J. P. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine, 393(7), 635–647. https://doi.org/10.1056/NEJMoa2502081
23. Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W.T. (2025). Once-weekly semaglutide 7· 2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology, 13(11), 949–963. https://doi.org/10.1016/S2213-8587(25)00226-8
24. Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., & Allen, S. E. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2511774
25. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., & Lingvay, I. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
26. Gonzales-Uribe, A., Ruiz-Cortez, R., Collantes-Silva, N., Olivero, L., Agarwal, R., Arambulo-Castillo, S., Garcia-Geng, A., Lyu, X., Mendoza-Quispe, D., Becerra-Gonzales, V., & Butrous, H. (2025). Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis. Clinical Research in Cardiology, 1–16. https://doi.org/10.1007/s00392-025-02710-8
27. Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F., Bakris, G., Baeres, F. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine, 391(2), 109–121. https://doi.org/10.1056/NEJMoa2403347
28. Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V. (2025). Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. New England Journal of Medicine, 392(21), 2089–2099. https://doi.org/10.1056/NEJMoa2413258
29. Dai, H., Li, Y., Lee, Y. A., Lu, Y., George, T. J., Donahoo, W. T., Lee, K. P., Nakshatri, H., Allen, J., Guo, Y., & Sun, R. C. (2025). GLP-1 receptor agonists and cancer risk in adults with obesity. JAMA Oncology, 11(10), 1186–1193. https://doi.org/10.1001/jamaoncol.2025.2681
30. Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., & Bunck, M. C. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine, 391(13), 1193–1205. https://doi.org/10.1056/NEJMoa2404881
31. El-Solh, A. A., Gould, E., Aibangbee, K., Jimerson, T., & Hartling, R. (2025). Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review. Expert Opinion on Pharmacotherapy, 26(1), 51–62. https://doi.org/10.1080/14656566.2024.2437525
32. Xie, Z., Yang, Z., Tian, D., & Chen, Y. (2025). Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact. Frontiers in Pharmacology, 16, 1618079. https://doi.org/10.3389/fphar.2025.1618079
33. Edison, P., Femminella, G. D., Ritchie, C. W., Holmes, C., Walker, Z., Ridha, B. H., Raza, S., Livingston, N. R., Nowell, J., Busza, G., & Frangou, E. (2021). Evaluation of liraglutide in the treatment of Alzheimer’s disease. Alzheimer’s & Dementia, 17, e057848. https://doi.org/10.1002/alz.057848
34. Chuansangeam, M., Phadungsaksawasdi, P., Park, H. J., & Yang, Y. H. (2025). Exploring the link between GLP-1 receptor agonists and dementia: A comprehensive review. Journal of Alzheimer’s Disease Reports, 9, 25424823251342182. https://doi.org/10.1177/25424823251342182
35. Chen, X., Zhao, P., Wang, W., Guo, L., & Pan, Q. (2024). The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis. The American Journal of Geriatric Psychiatry, 32(1), 117–127. https://doi.org/10.1016/j.jagp.2023.08.010
36. Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022). The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders. British Journal of Pharmacology, 179(4), 625–641. https://doi.org/10.1111/bph.15677
37. Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025). Weight reduction with GLP-1 agonists and paths for discontinuation while maintaining weight loss. Biomolecules, 15(3), 408. https://doi.org/10.3390/biom15030408
38. Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2024). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine, 69. https://doi.org/10.1016/j.eclinm.2024.102475
39. Cengiz, A., Wu, C. C., & Lawley, S. D. (2025). Alternative dosing regimens of GLP‐1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes, Obesity and Metabolism, 27(4), 2251–2258. https://doi.org/10.1111/dom.16229 
40. US Food & Drug Administration. (2025, April 28). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
41. Lupkin, S. (2024, September 6). Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptions. NPR. https://www.npr.org/sections/shots-health-news/2024/09/06/g-s1-21139/ozempic-wegovy-shortages